CHICAGO (EGMN) - Colorectal cancer patients whose tumors contain the wild-type KRAS gene responded better to treatment with cetuximab plus chemotherapy than did patients with tumor KRAS mutations, according to data presented during a June 1 plenary presentation at the annual meeting of the American Society of Clinical Oncology. More patients with wild-type KRAS tumors responded to cetuximab (Erbitux) plus the FOLFIRI (leucovorin, fluorouracil, and irinotecan) chemotherapy regimen (59%) than to FOLFIRI...